diabetic macular oedema
Ophthalmology · 2013–2024
12decisions
5medicines
7carried consumer input
13individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| aflibercept Visual impairment due to diabetic macular oedema (DMO). Treatment with intravitreal aflibercept 8 mg injection. | May 2024 | Recommended with restriction | 1 individuals Macular Disease Foundation Australia |
| aflibercept Visual impairment due to diabetic macular oedema (DMO). Patients must have documented visual impairment defined as best corrected visual acuity score between… | Nov 2024 | Recommended with restriction | none received |
| faricimab Treatment of patients with visual impairment due to diabetic macular oedema (DMO). | May 2022 | Recommended with restriction | input received Macular Disease Foundation Australia · Diabetes Australia |
| fluocinolone acetonide Diabetic macular oedema (DMO) in patients who are unsuitable for, contraindicated to, or have failed treatment with vascular endothelial growth factor (VEGF)… | Mar 2020 | Recommended with restriction | unclear |
| fluocinolone acetonide Diabetic macular oedema (DMO) in patients who are unsuitable for, contraindicated to, or have failed treatment with vascular endothelial growth factor (VEGF)… | Nov 2020 | Not recommended | input received |
| dexamethasone Vision impairment due to centre-involving diabetic macular oedema (DME) in patients with pseudophakic lenses or scheduled for cataract surgery, particularly… | Mar 2016 | Recommended with restriction | 2 individuals |
| dexamethasone Treatment of vision impairment due to centre-involving diabetic macular oedema (DME) in patients with pseudophakic lens or scheduled for cataract surgery. | Mar 2015 | Not recommended | 2 individuals |
| ranibizumab Treatment of visual impairment due to diabetic macular oedema (DME), as diagnosed by fluorescein angiography, in patients with best corrected visual acuity… | Jul 2014 | Recommended with restriction | 8 individuals |
| ranibizumab Treatment of visual impairment due to diabetic macular oedema (DME) and macular oedema secondary to retinal vein occlusion (RVO). | Mar 2014 | Deferred | unclear |
| aflibercept Treatment of visual impairment due to diabetic macular oedema (DME). | Nov 2014 | Recommended with restriction | input received |
| ranibizumab Treatment of visual impairment due to diabetic macular oedema (DME), to be administered by an ophthalmologist. | Mar 2013 | Not recommended | unclear |
| ranibizumab Treatment of visual impairment due to diabetic macular oedema (DME), as diagnosed by fluorescein angiography, in patients with best corrected visual acuity… | Nov 2013 | Deferred | no section in document |
Who spoke
Macular Disease Foundation Australia · Diabetes Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 10 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.